FHTX vs. ZYME, ADPT, GYRE, PSTX, OCS, NUVB, AVXL, ABCL, CVAC, and AVBP
Should you be buying Foghorn Therapeutics stock or one of its competitors? The main competitors of Foghorn Therapeutics include Zymeworks (ZYME), Adaptive Biotechnologies (ADPT), Gyre Therapeutics (GYRE), Poseida Therapeutics (PSTX), Oculis (OCS), Nuvation Bio (NUVB), Anavex Life Sciences (AVXL), AbCellera Biologics (ABCL), CureVac (CVAC), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry.
Foghorn Therapeutics vs.
Zymeworks (NYSE:ZYME) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, community ranking, analyst recommendations, profitability and dividends.
Zymeworks has a net margin of -182.75% compared to Foghorn Therapeutics' net margin of -357.53%. Foghorn Therapeutics' return on equity of 0.00% beat Zymeworks' return on equity.
Zymeworks received 254 more outperform votes than Foghorn Therapeutics when rated by MarketBeat users. Likewise, 67.75% of users gave Zymeworks an outperform vote while only 62.30% of users gave Foghorn Therapeutics an outperform vote.
Zymeworks has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.21, indicating that its stock price is 221% more volatile than the S&P 500.
Zymeworks currently has a consensus target price of $19.17, indicating a potential upside of 38.09%. Foghorn Therapeutics has a consensus target price of $13.80, indicating a potential upside of 220.19%. Given Foghorn Therapeutics' higher possible upside, analysts plainly believe Foghorn Therapeutics is more favorable than Zymeworks.
Foghorn Therapeutics has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.
92.9% of Zymeworks shares are held by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are held by institutional investors. 1.9% of Zymeworks shares are held by company insiders. Comparatively, 9.1% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Zymeworks had 8 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 8 mentions for Zymeworks and 0 mentions for Foghorn Therapeutics. Zymeworks' average media sentiment score of 1.18 beat Foghorn Therapeutics' score of 0.21 indicating that Zymeworks is being referred to more favorably in the media.
Summary
Zymeworks beats Foghorn Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Foghorn Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Foghorn Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FHTX) was last updated on 1/21/2025 by MarketBeat.com Staff
Free FHTX Stock Alerts